Pavan Asalapuram
Global hälsoforskare och translationell forskare som driver diagnostik, AMR, One Health-innovation och skalbara lösningar för infektionssjukdomar med hög sjukdomsbörda.
Om mig
AMR-övervakning brister i dag mindre på det vetenskapliga planet än på implementeringsnivån. Den diagnostiska infrastruktur, datainfrastruktur och de styrningsmodeller som krävs för att göra One Health-baserad AMR-detektion operativ inom kliniska, veterinärmedicinska och miljörelaterade sammanhang är fortfarande fragmenterade och svagt integrerade i de flesta hälso- och sjukvårdssystem.
Jag är forskare i gruppen Health Systems and Policy, ledd av professor Cecilia Stålsby Lundborg, vid Institutionen för global folkhälsa, Karolinska Institutet. Mitt arbete befinner sig i skärningspunkten mellan translationell diagnostik, One Health-baserad övervakningsarkitektur och implementering i hälsosystem, med särskilt fokus på hur hälso- och forskningssamarbetet mellan EU och Indien kan fungera som en proof-of-concept-modell för integrerad AMR-övervakning som är både vetenskapligt robust och operativt genomförbar i större skala.
Min bakgrund omfattar två decennier av utveckling och klinisk validering av diagnostiska plattformar för läkemedelsresistenta infektioner i Europa, Asien och Afrika, inklusive arbete som avancerat till WHO:s diagnostiska utvärderingsprocess för läkemedelsresistent tuberkulos. Detta arbete har stöttats av Bill & Melinda Gates Foundation och EU-finansierade forskningsprogram, inklusive H2020-MSCA-RISE och EU-COST.
Min nuvarande forskning omfattar utveckling och klinisk validering av SelektaDx™, en snabb multiplex molekylär plattform för AMR-detektion inom både human och veterinärmedicinsk hälsa, samt arbete med AI-baserad tidig riskdetektion och implementeringsanpassade beslutsstödssystem inom One Health-ramverk.
Jag välkomnar samarbeten med forskare, kliniker, folkhälsoaktörer och policyprofessionella som arbetar med AMR, One Health-diagnostik och implementeringspolicy på nationell och europeisk nivå.
Forskningsbeskrivning
Mina bredare forsknings- och innovationsintressen ligger i skärningspunkten mellan diagnostik, One Health, implementeringsvetenskap, hälsosystem, policy och AI-driven global hälsoinnovation.
Jag är särskilt intresserad av hur vetenskapliga och teknologiska framsteg kan översättas till tillgängliga, skalbara och hållbara lösningar för infektionssjukdomar, antimikrobiell resistens och andra stora folkhälsoutmaningar.
Mitt arbete bygger på uppfattningen att meningsfulla framsteg inom global hälsa kräver mer än enbart innovation. Det kräver starka samarbeten, systemtänkande, implementeringsstrategier och policyrelevans.
Genom detta integrerade angreppssätt vill jag bidra till nästa generation av verktyg och strategier som kopplar samman vetenskapliga upptäckter, data och verklig samhällsnytta i olika populationer och hälsosystem.
Undervisning
Handlett cirka 20 kandidatuppsats- och masteruppsatsstudenter/projekt.
Genomfört laboratoriepraktiska klasser för kandidatuppsats- och masterutbildningsstudenter.
Artiklar
- Article: FRONTIERS IN TUBERCULOSIS. 2025;:1536600Asalapuram P; Hoffner S
- Article: INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY. 2024;13(1):91-95Ramasubban G; Michael JS; Gupta R; Venkatesan M; Beauton AP; Hoffner S; Asalapuram P
- Article: ANALYTICA CHIMICA ACTA. 2018;1025:118-123Pavankumar AR; Zelenin S; Lundin A; Schulte T; Rajarathinam K; Rebellato P; Ardabili S; Salas J; Achour A; Russom A
- Article: ANALYTICAL CHEMISTRY. 2016;88(8):4277-4284Pavankumar AR; Engström A; Liu J; Herthnek D; Nilsson M
- Article: JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY. 2015;90(8):1521-1526Pavankumar AR; Singh L
- Article: CLEAN-SOIL AIR WATER. 2015;43(3):456-461Singh L; Sharma P; Pavankumar AR
- Article: JOURNAL OF MEDICAL MICROBIOLOGY. 2014;63(Pt 12):1595-1607Praekelt U; Reissbrodt R; Kresse A; Pavankumar A; Sankaran K; James R; Jesudason M; Anandan S; Prakasam A; Balaji V; Dutta S; Dutta S; Ramamurthy T; Fischer R; Sander P; Schaumann R; Navarro A; Williams P
- Article: INTERNATIONAL JOURNAL OF ENVIRONMENTAL SCIENCE AND TECHNOLOGY. 2014;11(4):873-880Bodlund I; Pavankumar AR; Chelliah R; Kasi S; Sankaran K; Rajarao GK
- Article: JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS. 2014;32(3):406-415Pavankumar AR; Kayathri R; Murugan NA; Zhang Q; Srivastava V; Okoli C; Bulone V; Rajarao GK; Ågren H
- Article: RSC ADVANCES. 2014;4(14):7136-7141Pavankumar AR; Norén J; Singh L; Gowda NKC
- Article: JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS. 2013;31(10):1182-1190Okoli C; Sengottaiyan S; Arul Murugan N; Pavankumar AR; Agren H; Kuttuva Rajarao G
- Article: BIOTECHNIQUES. 2012;52(3):167-172Pavankumar AR; Ayyappasamy SP; Sankaran K
- Article: ECOLOGICAL ENGINEERING. 2012;38(1):119-124Singh L; Pavankumar AR; Lakshmanan R; Rajarao GK
- Article: JOURNAL OF ANTIBIOTICS. 2009;62(7):377-384Alagumaruthanayagam A; Pavankumar AR; Vasanthamallika TK; Sankaran K
- Article: DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE. 2009;63(3):243-250Sankaran K; Banerjee S; Pavankumar AR; Jesudason M; Reissbrodt R; Williams PH
Alla övriga publikationer
- Published conference paper: INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY. 2026;S8(Special Issue 2026 – Abstracts):S8Pavan A; Nikhil S; Vasim A; Narayanan M; Stålsby Lundborg C
- Meeting summary: INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY. 2026;15(pS9):S9Asalapuram P
- Patent: 2025Portable and adaptive modular sterilization and lubrication system and applicationsAsalapuram P
- Patent: 2025One-Step Intercepting polymerase chain reaction (IntPCR) for simultaneous detection of wildtypes and selective point mutations and applications thereofAsalapuram P; Nikhil S
- Patent: 2025Analytical, clinical and interdisciplinary applications utilizing Shigella flexneri apyraseAsalapuram P
- Patent: 2024Novel coating and immobilization buffer for antigens and antibodies and uses thereofAsalapuram P; Nikhil S; Krishnan S
- Patent: 2022Modified Shigella apyrase and uses thereofAsalapuram P; Nikhil S
- Patent: 2017Diagnostic device and related methodAsalapuram P; Mats NB
- Patent: 2016Analytical and diagnostic methods utilizing Shigella flexneri apyraseAsalapuram P; Aman R
- Patent: 2009A method to detect the microbial resistance to antibiotics using fluorescenceAsalapuram P; Krishnan S; Alagumaruthanayagam A
- Review: FOOD TECHNOLOGY AND BIOTECHNOLOGY. 2008;46(2):125-145The Need and New Tools for Surveillance of Escherichia coli PathogensAsalapuram P; Krishnan Sankaran
- Report: 2005;:26Characterization of diarrhoeagenic E. coli (EPEC and EHEC) from incidences of infantile diarrhoeaAsalapuram P
Forskningsbidrag
- Exploring mlfoDx MDR-TB diagnostic platform in Africa and Latin American marketsBusiness Sweden1 November 2023
- Rapid Affordable Reliable-ELISA (RAR-ELISA) platform for the diagnosis of important helminthic infectionsDepartment of Biotechnology , Ministry of Science and Technology1 June 2023 - 31 December 2024
- Multiplex Diagnostic Platform for Accurate and Rapid Detection of MDR & pre-XDR-TBIPE Global1 January 2023
- Adaptable multi-flow diagnostics for multidrug-resistant TB using tongue swabsBill and Melinda Gates Foundation1 November 2022
- AdvanceTB: Towards an improvement in diagnostics and treatment strategies for tuberculosis control1 September 2022 - 30 September 2026Tuberculosis (TB) was the leading cause of mortality from an infectious disease globally before Coronavirus Disease 19. The unprecedented pandemic is a major setback for TB programmes and its impact has been tremendous in terms of disruption of timely diagnostic and intervention services, drop in notification numbers, treatment interruptions, inadequate patient’s treatment follow-up and increase in mortality. In order to mitigate this impact more efforts and resources have to be allocated. Currently, no COST Action exists to address the complexity of TB management, offering an advantage to this proposal. The ADVANCE-TB is a research network that offers opportunities for collaboration between clinicians, academic researchers from interdisciplinary backgrounds, industry and non-governmental organizations to achieve breakthroughs difficult to obtain by individual partners, allowing a better understanding of the underlying host-pathogen mechanisms, enabling the transfer of basic science into innovative applications and allowing product development and clinical validation. The Action focuses on 1).developing best clinical practices and experimental standardization protocols, including harmonized biobanking procedures2).stimulating the development and optimization of products for diagnostic and therapy/monitoring3).disseminate knowledge and allow capacity-building through different types of workshops, training schools and short-term scientific missions, prioritizing early career investigators. The tasks are distributed in 4 working groups (WG). Briefly, WG1 will be focused on the characterization of patient’s cohorts, WG2 will be devoted to the development and evaluation of novel diagnostic methods, WG3 will be centred on the design of novel therapeutical strategies and WG4 will be responsible for dissemination and communication activities.
- mfloDx: An Adaptable Multiflow Diagnostic Platform to Genetically Identify Drug Resistant InfectionEuropean Commission Directorate-General for Research and Innovation1 January 2020 - 30 June 2024
- mfloDx: An Adaptable Multiflow Diagnostic Platform to Genetically Identify Drug Resistant InfectionEuropean Commission Directorate-General for Research and Innovation1 October 2019 - 29 February 2020
- RCA-ADT diagnostic platform for the rapid detection of enteric pathogensEPSRC grant1 January 2016 - 31 December 2017
- A multiplex diagnostic test for multi-drug/extensively drug-resistant tuberculosisVinnova1 November 2013 - 30 September 2016
- INNOVA4TB: Innovative development to enable individualised tuberculosis treatmentEuropean Commission Directorate-General for Research and Innovation
- Integrated fluidic-array-microsystem for rapid screening of extended spectrum β-lactamases and multidrug resistant pathogens.KTH - Life Science Platform
- Real-time wireless biosensor networks for the surveillance of microbes and pollutants in drinking water supply linesKTK Life Science Technology Platform
Anställningar
- Anknuten till Forskning, Global folkhälsa, Karolinska Institutet, 2022-
- Anknuten till Forskning, Global folkhälsa, Karolinska Institutet, 2024-2026
- CEO, Mitti Lifetek AB, 2019-2024
- Founder & CEO, EMPE Diagnostics AB, 2016-2024
- Postdoctor, Stockholm University, 2013-2016
- Researcher, Biothema AB & KTH, 2012-2013
- Postdoctor, Molecular Diagnostics, Royal Institute of Technology, 2010-2011
Examina och utbildning
- PhD, Clinical Biotechnology, Anna University, Chennai, 2010
- M.S. (res), Clinical Biotechnology, Anna University, Chennai, 2006
- EPGD in Hospital & Health Care Management, Loyola Institute of Business Administration (LIBA), 2002
- B. Pharmacy, Pharmacy, Madras Medical College, Dr MGR Medical University, 2001
